Carcinoma in situ, bladder (controls excluding all cancers)

Endpoint Browser PheWeb

CD2_INSITU_BLADDER_EXALLC

No definition available.

Endpoint definition

↥

FinnGen phenotype data

individuals

Apply sex-specific rule None

Check conditions

not C3_BLADDER

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D09.0&

Hospital discharge: ICD-9 2337

Cause of death: ICD-10 D09.0&

Cause of death: ICD-9 2337

Cancer registry: Topography ICD-O-3 C67

Cancer registry: Morphology ICD-O-3 ANY

Cancer registry: Behaviour codes 2

3 out of 7 registries used, show all original rules.

Check minimum number of events None

Include endpoints None

Remove individuals based on genotype QC

695

CD2_INSITU_BLADDER_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 3

First used in FinnGen datafreeze DF9

Parent code in ICD-10 D09

NAME	CD2_INSITU_BLADDER_EXALLC
CONTROL_EXCLUDE	C3_CANCER\|C3_CANCER_WIDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS	!C3_BLADDER
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D090
HD_ICD_9	2337
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D090
COD_ICD_9	2337
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO	C67
CANC_TOPO_EXCL
CANC_MORPH	ANY
CANC_MORPH_EXCL
CANC_BEHAV	2

No upset plot: script not run.

No upset table: script not run.

Similar endpoints

↥

List of similar endpoints to Carcinoma in situ, bladder (controls excluding all cancers) based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

Carcinoma in situ, bladder

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	695	127	568
Unadjusted prevalence (%)	0.17	0.06	0.31
Mean age at first event (years)	70.48	67.69	71.10

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.07	3.21 [1.79, 5.76]	9.6e-5	84
15 years	0.01	1.26 [0.68, 2.32]	4.6e-1	30
5 years	0.00	3.39 [1.83, 6.29]	1.0e-4	44
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_INSITU_BLADDER_EXALLC – Carcinoma in situ, bladder (controls excluding all cancers)
GWS hits: 2

Survival analyses between endpoints

↥

Plot

before Carcinoma in situ, bladder (controls excluding all cancers)
after Carcinoma in situ, bladder (controls excluding all cancers)

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Carcinoma in situ, bladder (controls excluding all cancers)

↥

Endpoint not on priority list, no data to show.

≡ Risteys

R10

R9

R8

R7

R6

R5

R4

R3